2 New Links to HCV Abstracts

[Guest guest]

Investigational Direct-Acting Antiviral BMS-790052 Plus PEG-Interferon Alfa and

Ribavirin Achieved Up to 92% Sustained Virologic Response

From the PharmaLive.com News Archive - Mar. 31, 2011

Bristol-Myers Squibb Company today announced results from a Phase II clinical

trial in which treatment with the investigational direct-acting antiviral

BMS-790052, an NS5A replication complex inhibitor, in combination with

PEG-Interferon alfa and ribavirin (RBV), achieved sustained virologic response

12 weeks post-treatment (SVR12) in up to 92% of treatment-naïve patients

chronically infected with hepatitis C (HCV) genotype 1 (10 mg dose arm, n=12).

Victrelis Added to Peginterferon Alfa-2a and Ribavirin Achieved Significantly

Higher SVR Rates

From the PharmaLive.com News Archive - Mar. 31, 2011

Merck known as MSD outside of the United States and Canada, reported that final

results from a Phase III study of Victrelis added to peginterferon alfa-2a

(Pegasys) and ribavirin therapy demonstrated significantly higher sustained

virologic response (SVR)1 rates in adult patients who failed previous treatment

for chronic hepatitis C virus (HCV) genotype 1 compared to a control group

receiving peginterferon alfa-2a and ribavirin alone, the primary endpoint of the

48-week study.

[Guest guest]

Investigational Direct-Acting Antiviral BMS-790052 Plus PEG-Interferon Alfa and

Ribavirin Achieved Up to 92% Sustained Virologic Response

From the PharmaLive.com News Archive - Mar. 31, 2011

Bristol-Myers Squibb Company today announced results from a Phase II clinical

trial in which treatment with the investigational direct-acting antiviral

BMS-790052, an NS5A replication complex inhibitor, in combination with

PEG-Interferon alfa and ribavirin (RBV), achieved sustained virologic response

12 weeks post-treatment (SVR12) in up to 92% of treatment-naïve patients

chronically infected with hepatitis C (HCV) genotype 1 (10 mg dose arm, n=12).

Victrelis Added to Peginterferon Alfa-2a and Ribavirin Achieved Significantly

Higher SVR Rates

From the PharmaLive.com News Archive - Mar. 31, 2011

Merck known as MSD outside of the United States and Canada, reported that final

results from a Phase III study of Victrelis added to peginterferon alfa-2a

(Pegasys) and ribavirin therapy demonstrated significantly higher sustained

virologic response (SVR)1 rates in adult patients who failed previous treatment

for chronic hepatitis C virus (HCV) genotype 1 compared to a control group

receiving peginterferon alfa-2a and ribavirin alone, the primary endpoint of the

48-week study.